Halia Therapeutics has developed HT-4253 to prevent Alzheimer's disease in people carrying the APOE4 genetic risk variant by mimicking a naturally protective mechanism observed in genetically susceptible individuals who remain disease-free. The approach targets neuroinflammation and tau pathology years before symptom onset, marking a strategic shift from treatment after diagnosis to prevention during the asymptomatic phase.
Key Points
- HT-4253 targets LRRK2 protein to recreate natural protection seen in APOE4 carriers without disease
- Preclinical data show reduced neuroinflammation, tau changes, and restored microglial clearance func
- Phase 2a trial recruits cognitively healthy APOE4 carriers using blood biomarkers to identify early
Longevity Analysis
This work embodies a fundamental reorientation in neurodegenerative disease strategy: identifying and intervening on biological dysfunction years before cognitive symptoms manifest. By studying people who carry high genetic risk yet remain protected, researchers are extracting natural blueprints for disease prevention rather than attempting reversal of established pathology. Blood-based biomarkers now enable detection of these early pathological changes in asymptomatic individuals, creating a practical pathway to prevent decline in brain function before it becomes irreversible. This approach addresses a critical bottleneck in longevity medicine—the gap between understanding risk and being able to act on it while tissues remain responsive to intervention.
Original published by Longevity.Technology, by Kyle Umipig.